- $2.92m
- -$56.95m
- $2.13m
- 47
- 39
- 26
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.06 | ||
| Price to Tang. Book | 0.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.46% | ||
| Return on Equity | -70.48% | ||
| Operating Margin | -13510.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.98 | 10.94 | 8.19 | 4.81 | 2.13 | n/a | 13 | -2.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Talis Biomedical Corporation is a molecular diagnostic company. The Company is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Directors
- Robert Kelley CEO (49)
- Rustem Ismagilov CFD (47)
- J. Roger Moody CFO (53)
- Karen Flick SVP (52)
- Douglas Liu SVP (59)
- Ramesh Ramakrishnan SVP (61)
- Felix Baker DRC (52)
- Raymond Cheong DRC (39)
- Kimberly Popovits DRC (62)
- Melissa Gilliam IND (55)
- Jeryl Hilleman IND (63)
- Matthew Posard IND (48)
- Randal Scott IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 26th, 2013
- Public Since
- February 12th, 2021
- No. of Shareholders
- 69
- No. of Employees
- 99
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 1,822,153
- Address
- 1375 West Fulton Market, Suite 700, CHICAGO, 60607
- Web
- https://talisbio.com/
- Phone
- +1 6504333000
- Auditors
- Ernst & Young LLP
Upcoming Events for TLIS
Similar to TLIS
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Talis Biomedical share price?
As of Today at 23:35 UTC, shares in Talis Biomedical are trading at $1.60. This share price information is delayed by 15 minutes.
How has the Talis Biomedical share price performed this year?
Shares in Talis Biomedical last closed at $1.60 and the price had moved by -82.02% over the past 365 days. In terms of relative price strength the Talis Biomedical share price has underperformed the S&P500 Index by -83.33% over the past year.
What are the analyst and broker recommendations for Talis Biomedical?
The overall consensus recommendation for Talis Biomedical is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Talis Biomedical dividend yield?
Talis Biomedical does not currently pay a dividend.
Does Talis Biomedical pay a dividend?
Talis Biomedical does not currently pay a dividend.
When does Talis Biomedical next pay dividends?
Talis Biomedical does not currently pay a dividend.
How do I buy Talis Biomedical shares?
To buy shares in Talis Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Talis Biomedical?
As of the previous close price of $1.60, shares in Talis Biomedical had a market capitalisation of $2.92m.
Where are Talis Biomedical shares listed?
Here are the trading details for Talis Biomedical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TLIS
What kind of share is Talis Biomedical?
Based on an overall assessment of its quality, value and momentum Talis Biomedical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Talis Biomedical share price forecast for 2025?
The analyst consensus target price for shares in Talis Biomedical is $5.00. That is 212.5% above the last closing price of $1.60.
Analysts covering Talis Biomedical currently have a consensus Earnings Per Share (EPS) forecast of -$23.32 for the next financial year.
Find out moreWhat is the trend in the Talis Biomedical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Talis Biomedical. Over the past six months, its share price has underperformed the S&P500 Index by -5.07%.
As of the last closing price of $1.60, shares in Talis Biomedical were trading -64.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Talis Biomedical PE Ratio?
The Talis Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Talis Biomedical?
Talis Biomedical's management team is headed by:
- Robert Kelley - CEO
- Rustem Ismagilov - CFD
- J. Roger Moody - CFO
- Karen Flick - SVP
- Douglas Liu - SVP
- Ramesh Ramakrishnan - SVP
- Felix Baker - DRC
- Raymond Cheong - DRC
- Kimberly Popovits - DRC
- Melissa Gilliam - IND
- Jeryl Hilleman - IND
- Matthew Posard - IND
- Randal Scott - IND